IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma
Source: Cancer Network, November 2024
Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.
Therapy with IMA203, an investigational preferentially expressed antigen in melanoma (PRAME)–targeting T-cell therapy, yielded sustained responses among patients with melanoma and other solid tumors, according to findings from the phase 1 IMA203-101 study (NCT03686124) presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC).
IMA203 produced a confirmed overall response rate (ORR) of 54% and 60% among patients with cutaneous (n = 13) and uveal melanoma (n = 10), respectively. In each respective patient group, the unconfirmed ORR was 62% and 60%, tumor shrinkage occurred in 85% and 100%, and the disease control rate (DCR) at week 6 was 92% and 90%.